Media
BetaLife wins Cytiva’s first BioChallenge Competition in Southeast Asia by Cytiva on 7th Jun 2023 (https://www.cytivalifesciences.com/en/us/news-center/betalife-wins-cytivas-biochallenge-competition-10001)
BetaLife was featured in science news “BetaLife and A*STAR Collaborate to develop next generation cell-based therapy for diabetes treatment” by Bioengineer.org on 22nd March 2023 (https://bioengineer.org/betalife-and-astar-collaborate-to-develop-next-generation-cell-based-therapy-for-diabetes-treatment).
Our Co-Founder Dr Adrian Teo featured in a video “Supporting Science Globally: A look into how scientists in Singapore are using organoids” by STEMCELL Technologies on 20th August 2020 (https://www.youtube.com/watch?v=GzMcF4QUdC8).
Our Co-Founder Dr Adrian Teo featured in a story “Entrepreneurial King of the Lab” in the 3rd February 2020 issue of SGInnovate’s white paper on deep tech talent (https://www.sginnovate.com/blog/future-jobs).
Our Co-Founder Dr Adrian Teo and his research team’s work featured in a story “Weaponizing Stem Cells in the War on Diabetes” in Issue 15, July – December 2019, of A*STAR Research.
Our Co-Founder Dr Adrian Teo featured in a cover story “Stem Cells Gaining Importance” in the August 2019 issue of BioSpectrum Asia on stem cell therapies in APAC.
Our Co-Founder Dr Adrian Teo featured on The Stem Cell Podcast Episode 142: “Beta-Cell Proliferation and Diabetes” (https://stemcellpodcast.com/ep-142-b-cell-proliferation-and-diabetes-featuring-dr-adrian-teo; https://content.blubrry.com/stemcellpodcast/SCP142.mp3) held on May 14, 2019.
Our Co-Founders Dr Adrian Teo and Dr Natasha Ng’s research work featured in a story https://research.a-star.edu.sg/articles/highlights/getting-to-the-roots-of-early-onset-diabetes/
Our Press Release
BetaLife Pte Ltd bolsters leadership with appointment of new CSO and Acting CEO
BetaLife Pte Ltd has appointed Dr Natasha Hui Jin Ng (吴荟瑾博士) as Chief Scientific Officer (CSO) and acting Chief...
BetaLife and A*STAR Collaborate to Develop Next Generation Cell-based Therapy for Diabetes Treatment
BetaLife has acquired the rights to human iPSC technology and cell lines from A*STAR BetaLife and A*STAR sign research...